March 14 | 2019
Notice of extraordinary general meeting in 2cureX AB (publ)
Read more
March 14 | 2019
Kallelse till extra bolagsstämma i 2cureX AB (publ)
Read more
March 12 | 2019
2cureX utvidgar verksamheten till förebyggande cancermedicin
Read more
March 12 | 2019
2cureX expands its activities to preventive cancer medicine
Read more
March 1 | 2019
2cureX offentliggör bokslutskommuniké för räkenskapsåret 2018
Read more
March 1 | 2019
2cureX publishes year-end report for the fiscal year 2018
Read more
February 20 | 2019
Correction – Lack of reference to MAR – 2cureX reports positive results from an ongoing clinical trial in heavily pre-treated colorectal cancer patients
Read more
February 20 | 2019
Correction – Lack of reference to MAR – 2cureX meddelar positiva resultat från pågående klinisk studie med kraftigt förbehandlade kolorektalcancerpatienter
Read more
January 16 | 2019
2cureX strengthens the organisation via the recruitment of a CFO
Read more
January 16 | 2019
2cureX stärker organisationen genom rekrytering av CFO
Read more
December 10 | 2018
2cureX is accelerating the launch of IndiTreat®
Read more
December 10 | 2018
2cureX accelererar lanseringen av IndiTreat®
Read more
November 23 | 2018
2cureX AB publishes interim report for January – September 2018
Read more
November 23 | 2018
2cureX AB offentliggör delårsrapport för januari – september 2018
Read more
November 16 | 2018
Vejle universitetssjukhus och 2cureX har erhållit godkännande att inleda en klinisk studie i bukspottkörtelcancer
Read more
November 16 | 2018
The University Hospital, Vejle Hospital and 2cureX have received approval to start a clinical trial in pancreatic cancer
Read more
October 9 | 2018
2cureX announces CE-IVD marking of its IndiTreat test
Read more
October 9 | 2018
2cureX meddelar godkänd CE-IVD-märkning av sitt IndiTreat-test
Read more